QuatRx Pharmaceuticals

About QuatRx Pharmaceuticals

QuatRx Pharmaceuticals, established in 2000, was a biopharmaceutical firm headquartered in Ann Arbor, Michigan, that concentrated on developing and commercializing compounds for endocrine, metabolic, and cardiovascular disorders. The company was co-founded by Robert L. Zerbe, who served as its CEO and President. The founding team's extensive experience, including involvement in the development of major pharmaceutical products like Lipitor, shaped the company's strategic focus. QuatRx's business model was centered on in-licensing promising drug candidates, advancing them through clinical development, and then seeking partnerships for commercialization.

The company's portfolio included several clinical-stage product candidates. Its most prominent asset was Ospemifene (marketed as Ophena™), a selective estrogen receptor modulator (SERM) developed for treating post-menopausal vulvovaginal atrophy (VVA), a condition causing symptoms like painful intercourse. Unlike existing treatments, Ospemifene was a non-estrogen oral therapy, designed to provide the benefits of estrogen on the vaginal tissue while minimizing effects on other tissues. Other pipeline products included fispemifene for testosterone deficiency in men, and QRX-431, a compound for lipid disorders and obesity.

QuatRx successfully raised significant capital through multiple funding rounds, attracting investments from prominent venture capital firms such as Venrock, Frazier Healthcare Ventures, and MPM Capital, totaling over $160 million. A key milestone was the acquisition of the Finnish company Hormos Medical in 2005, which expanded its pipeline with compounds like Ospemifene. In a strategic move in March 2010, QuatRx entered into a major licensing agreement with the Japanese pharmaceutical company Shionogi & Co., Ltd. This deal, valued at over $125 million including an upfront payment of $25 million and potential milestones, granted Shionogi worldwide rights to develop and market Ospemifene. Following successful clinical trials, Ospemifene received FDA approval in February 2013. Ultimately, QuatRx Pharmaceuticals was acquired by Shionogi & Co. in 2017.